Israel's Teva Pharmaceutical Industries Ltd.: Success with a Hybrid Business Model
|
Code :BSM0045
|
Region : Israel
|
||||
 |
 |
 |
 OR |
||
|
Introduction:The pharmaceutical industry, considered very profitable, has changed in the 21st century. With most of the blockbuster drugs nearing patent expiration and the R&D pipelines of the big pharma companies going dry, there is intense competition between generic drug manufacturers and big pharma companies. As a result, the structure of the pharmaceutical industry has been altered with big pharma companies entering the generic domain and vice versa. Teva Pharmaceutical Industries Ltd. (Teva), one of the largest generic drug manufacturers, has succeeded in this scenario by employing a hybrid business model of both a generic and patented drug manufacturer. In 2008, the company announced its plans to expand into Japan, which is opening up its market for generics due to increasing healthcare costs. The Japanese pharmaceutical industry, however, has been traditionally conservative towards the use of generics. Will Teva be able to succeed in the highly regulated market of Japan? What role will the company's hybrid model play in the company's success in the future? |
|
| For Case Books
Click Here >> For Case eBooks Click Here >> |
|
